The US biologic market landscape is undergoing dramatic change. When the Patient Protection and Affordable Care Act (Affordable Care Act) was passed in 2013, it amended the Public Health Service Act (PHS Act), creating an abbreviated approval pathway for biological products that are “biosimilar” or “interchangeable” with an FDA-approved biological product. This opened the door…